Loading...

PHRM

PHR

PHARMING GROUP NV

(PHAR)

2025 6-K

Show Summary

Summary

Leadership Change

2 Sep '25

Strong Q2 Growth

31 Jul '25

Webcast Announcement

24 Jun '25

AGM Results Announcement

11 Jun '25

First Quarter Results

8 May '25

AGM Announcement

30 Apr '25

Upcoming Presentations

25 Apr '25

Positive NICE Recommendation

23 Apr '25

Annual Report Filing

3 Apr '25

Phase II Trial Initiated

20 Mar '25

Financial Results Update

13 Mar '25

Management Change

4 Mar '25

Ownership Increase

20 Feb '25

Cash Offer Completed

7 Feb '25

Extraordinary Meeting Notif...

21 Jan '25

Leadership Change

21 Jan '25

Cash Offer Announcement

16 Dec '24

Positive Trial Results

11 Dec '24

Q3 Earnings Update

24 Oct '24

Clinical Trial Launch

10 Oct '24

UK Approval Granted

26 Sep '24

Financial Growth Update

1 Aug '24

Regulatory Update

30 May '24

AGM Results Approved

21 May '24

Bond Redemption Announcement

15 May '24

Financial Growth Report

8 May '24

Bond Offering Launch

25 Apr '24

Innovation Award

24 Apr '24

Trial Enrollment Completed

8 Apr '24

Annual Report Filing

4 Apr '24

Pharming 2023 Report

14 Mar '24

2023 Guidance Update

8 Jan '24

External Links:

SEC

Pharming Group N.V. announced presentations, including Phase III clinical data for leniolisib in pediatric patients with APDS, at the Clinical Immunology Society meeting from May 1-4, 2025, with one presentation by Shanmuganathan Chandrakasan on May 2, showing the drug’s potential benefits.

AI Assistant

PHARMING GROUP NV

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.